Finally, within the *0401 positive participants, there were no significant differences between anti-CCP3(−) Controls and At-Risk participants in any antibody positivity although there were multiple positive antibodies to individual antigens, or groups of antigens, in Early RA participants compared to At-Risk at both the p < 0.05 and FDR-adjusted p-value levels. The gene discussed is AGBL3; the disease is rheumatoid arthritis.